Clinical Trial

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Completed
View on ClinicalTrials.gov →
Summary
This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).
Protocol Amendment History 4 changes
critical Trial completed 2026-05-16
notable Enrollment reduced: 400 -> 253 participants 2026-05-16
notable Primary completion moved earlier: 2026-02-23 -> 2026-01-23 2026-05-16
minor Completion moved earlier: 2026-02-23 -> 2026-01-23 2026-05-16
Trial Details
NCT Number NCT07238322
Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited
Conditions Retrospective Study, Glioma, Brain Neoplasms
Enrollment 253 participants
Start Date 2025-09-22
Primary Completion 2026-01-23 (estimated)
Study Completion 2026-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-05-15